Exploring the Utility of a Novel BRAF Test in Patients With Melanoma
There will be no extra clinic visits for this study. These research blood samples will be
drawn at the same time as your regularly scheduled blood draws that are part of standard
care for melanoma.
About 2 to 4 teaspoons of blood will be drawn for each research sample.
Depending on which group you are in, you will have either a one time blood draw or ongoing
blood work for 1-2 years.
Observational Model: Case Control, Time Perspective: Prospective
Determine Specificity and Sensitivity of Blood Based Assay
To determine the specificity and sensitivity of the blood based assay vis-a-vis tissue based BRAF analysis in patients with advanced and high-risk melanoma
Ryan Sullivan, MD
Massachusetts General Hospital
United States: Institutional Review Board
|Beth Israel Deaconess Medical Center||Boston, Massachusetts 02215|
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|